NP | Jotup

XTM Provides Update on Status of Financial Statements

Retrieved on:

Mercoledì, Maggio 15, 2024

Software, Internet, Payments, Banking, Professional Services, Technology, Fintech, Mobile, Wireless, Corporation, XTM, Ontario Securities Commission, OSC, Bank statement, PAID, Audit

XTM Inc. ("XTM" or the "Corporation") (QB: XTMIF / CSE: PAID / FSE: 7XT) is providing an update to its previously announced management cease trade order (the "MCTO") granted by the Ontario Securities Commission (the “OSC”) under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203").

Key Points:

XTM Inc. ("XTM" or the "Corporation") (QB: XTMIF / CSE: PAID / FSE: 7XT) is providing an update to its previously announced management cease trade order (the "MCTO") granted by the Ontario Securities Commission (the “OSC”) under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203").
The MCTO does not affect the ability of other shareholders to trade their securities.
The Corporation has not yet filed the Required Documents, however XTM is working diligently with its auditors and expects that the Required Documents will be filed as soon as possible.
As previously reported, the delay is related to audit procedures and a quality review to support reliance on third party service organizations.

Kerecis to Present Scientific and Clinical Updates on Fish-Skin Grafts at the Symposium on Advanced Wound Care Spring

Retrieved on:

Martedì, Maggio 14, 2024

Kerecis , the pioneer in the use of fish skin and fatty acids for tissue regeneration and protection, will unveil its latest scientific and clinical updates, including trial results, at the upcoming Symposium on Advanced Wound Care (SAWC) Spring.

Key Points:

Kerecis , the pioneer in the use of fish skin and fatty acids for tissue regeneration and protection, will unveil its latest scientific and clinical updates, including trial results, at the upcoming Symposium on Advanced Wound Care (SAWC) Spring.
Kerecis will exhibit at booth 419 at SAWC, which will take place from May 14 to 18 in Orlando, Florida.
“Our ongoing research and data underscore significantly improved healing times, reduced complications, and enhanced patient outcomes across different clinical settings.
During a hands-on skills lab, Kerecis medical affairs program managers will demonstrate Kerecis products, highlighting advanced applications in real-world clinical settings.

KRAFTON Achieves Record-high Sales of 665.9 billion KRW in 1Q24

Retrieved on:

Mercoledì, Maggio 15, 2024

KRAFTON recorded its 1Q24 sales of 665.9B South Korean Won, Operating Profit (OP) of 310.5B KRW, and Net Profit (NP) of 348.6B KRW following the Korean International Financial Reporting Standards (K-IFRS).

Key Points:

KRAFTON recorded its 1Q24 sales of 665.9B South Korean Won, Operating Profit (OP) of 310.5B KRW, and Net Profit (NP) of 348.6B KRW following the Korean International Financial Reporting Standards (K-IFRS).
Consolidated sales climbed 24.6% QoQ, setting a record-high quarterly sales.
Sales by business division are as follows: PC/Console 255.2B KRW, Mobile 402.3B KRW and Others 8.4B KRW.
Through various live services using PUBG: BATTLEGROUNDS IP, there has been high growth in all areas, including sales and traffic.

Cardurion Pharmaceuticals Presents Positive Clinical Results from CARDINAL‑HF Phase 2a Clinical Trial of PDE9 Inhibitor in Patients With Heart Failure

Retrieved on:

Sabato, Maggio 11, 2024

Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced the presentation of positive clinical data from CARDINAL‑HF, the first Phase 2 proof-of-concept clinical trial of a phosphodiesterase-9 (PDE9) inhibitor in patients with heart failure.

Key Points:

Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced the presentation of positive clinical data from CARDINAL‑HF, the first Phase 2 proof-of-concept clinical trial of a phosphodiesterase-9 (PDE9) inhibitor in patients with heart failure.
Key findings presented include:
CRD-740 was generally well-tolerated in patients with HFrEF, a disease representing approximately one-half of patients with chronic heart failure.
Based on the results of the CARDINAL-HF Phase 2a trial, Cardurion has launched two Phase 2 clinical trials in 640 patients, including a dose-ranging trial in patients with HFrEF and a proof-of-concept trial in patients with heart failure with preserved ejection fraction (HFpEF).
“We thank our patients and investigators for their partnership and look forward to continuing the development of our PDE9 inhibitors to improve outcomes for patients.”

Remission Medical Launches a Navigator Service

Retrieved on:

Venerdì, Maggio 10, 2024

Insurance, Patient, PIN, CMMI, CMS, Rheumatism, Work, Arthralgia, Practitioner, App, Remission, MD, Autoimmunity, TTD, Arthritis, CDC, Quality of life, TTI, Medicine, Nursing

RICHMOND, Va., May 10, 2024 /PRNewswire/ -- Remission Medical, the largest national virtual clinic offering diagnosis and longitudinal care in Rheumatology, powered by video visits and a technology platform focused on escalation avoidance, is now in its third year.

Key Points:

"A big learning we've had since our founding in 2022 is that not every patient issue rises to the level of a video visit," said Kyle Harner, MD, Chief Medical Officer of Remission Medical.
"We knew wait times to see a Rheumatologist for diagnosis and longitudinal care were very long in America," said Blake Wehman, Founder & CEO of Remission Medical.
But a significant portion of a patient's journey to low disease activity or remission should occur outside the four walls of a medical office, where texting can be effective and efficient," said Blake Wehman, CEO of Remission Medical and proud Remission Medical patient himself.
Remission Medical partners with hospital systems nationwide to speed Time to Diagnosis (TTD) and Time to Treatment Initiation (TTI) in Rheumatic Disease, and is based in Richmond, Virginia.

Ultra Lithium Provides Bi-Weekly Default Status Report

Retrieved on:

Sabato, Maggio 4, 2024

Lithium, CFO, National Policy, News, National instrument, Bank statement

VANCOUVER, British Columbia, May 03, 2024 (GLOBE NEWSWIRE) -- Ultra Lithium Inc. (TSXV: ULT OTCQB: ULTXF Frankfurt: QFB) (“Ultra Lithium” or the “Company”) is providing this bi-weekly default status report in accordance with National Policy 12-203 Management Cease Trade Orders (“NP 12-203”).

Key Points:

VANCOUVER, British Columbia, May 03, 2024 (GLOBE NEWSWIRE) -- Ultra Lithium Inc. (TSXV: ULT OTCQB: ULTXF Frankfurt: QFB) (“Ultra Lithium” or the “Company”) is providing this bi-weekly default status report in accordance with National Policy 12-203 Management Cease Trade Orders (“NP 12-203”).
The management cease trade order has been granted by the Company’s principal regulator, the British Columbia Securities Commission.
The Company experienced some delays obtaining documents from Argentina that its auditors require to complete the audit.
Pursuant to NP 12-203, the Company must file bi-weekly default status reports in the form of further news releases during the period of the MCTO.

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Retrieved on:

Giovedì, Maggio 2, 2024

IMV, Ontario Securities Commission, Acquisition, National instrument, Intellectual property, Bank statement, FRA, Music

Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

Key Points:

Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings and the Required Interim Filings by May 13, 2024.
The Company is working with its auditor in order to file the Required Annual Filings and with its accountants in order to file the Required Interim Filings.

BTQ TECHNOLOGIES CORP. PROVIDES BI-WEEKLY MCTO STATUS UPDATE

Retrieved on:

Giovedì, Maggio 2, 2024

BTQ, BCSC, Bank statement, CBOE

The Company had anticipated filing the Annual Filings by May 2, 2024; however, the auditor of the Company has advised that it will not be in a position to complete the audit by May 2, 2024, and has advised that it requires additional time to complete the audit.

Key Points:

The Company had anticipated filing the Annual Filings by May 2, 2024; however, the auditor of the Company has advised that it will not be in a position to complete the audit by May 2, 2024, and has advised that it requires additional time to complete the audit.
As a result, the Company now anticipates filing the Annual Filings on or before May 24, 2024.
The Company anticipates filing the Interim Filings on or before May 29, 2024.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement or the Company's subsequent press releases on April 4 and April 17, 2024 with respect to the issuance of the MCTO.

GameOn Granted MCTO by BCSC

Retrieved on:

Mercoledì, Maggio 1, 2024

Annual, News, National Policy, Bank statement

VANCOUVER, BC, April 30, 2024 /PRNewswire/ -- GameOn (CSE: GET) (OTCQB: GMETF), announces that, further to its news release dated April 15, 2024 (the "Announcement"), its principal regulator, the British Columbia Securities Commission, has accepted the Company's application for, and has granted, a management cease trade order (the "MCTO").

Key Points:

VANCOUVER, BC, April 30, 2024 /PRNewswire/ -- GameOn (CSE: GET) (OTCQB: GMETF), announces that, further to its news release dated April 15, 2024 (the "Announcement"), its principal regulator, the British Columbia Securities Commission, has accepted the Company's application for, and has granted, a management cease trade order (the "MCTO").
Reasons for the anticipated delay include additional due diligence with respect to the reporting of the Company's new commercial agreements and blockchain grants.
The MCTO restricts the Chief Executive Officer and Chief Financial Officer from all trading in securities of the Company until such time as the Annual Filings have been filed by the Company and the MCTO has been lifted.
The MCTO does not affect the ability of other shareholders of the Company to trade in securities of the Company.

CATL and Beijing Hyundai sign strategic agreement on EV batteries

Retrieved on:

Domenica, Aprile 28, 2024

Auto China, CATL, EV, Partnership, Hyundai, Growth, CTP, Automotive industry

BEIJING, April 28, 2024 /PRNewswire/ -- On April 25, 2024, CATL (SZ:300750) and Beijing Hyundai signed a strategic partnership agreement at Auto China 2024 to cooperate on Beijing Hyundai's EV projects and to power future Beijing Hyundai electric models with CATL batteries.

Key Points:

BEIJING, April 28, 2024 /PRNewswire/ -- On April 25, 2024, CATL (SZ:300750) and Beijing Hyundai signed a strategic partnership agreement at Auto China 2024 to cooperate on Beijing Hyundai's EV projects and to power future Beijing Hyundai electric models with CATL batteries.
As a joint venture with a deep presence in China for 21 years, Beijing Hyundai has sold over 12 million vehicles in China, proving reliable vehicle manufacturing capabilities.
Since its cooperation with CATL began in 2017, Beijing Hyundai has launched a series of popular models with cumulative sales exceeding 200,000 units.
CATL will leverage its technological advantages to work with Beijing Hyundai to create high-quality automotive products and support Beijing Hyundai's business growth in China.